Navigation Links
G-CON Manufacturing, Inc. Announces Maik Jornitz as President
Date:7/29/2014

Bryan, TX (PRWEB) July 29, 2014

G-CON Manufacturing Inc., the standard in design and production of autonomous modular cleanrooms, today announced a new leadership appointment designed to drive the company’s ambitious growth initiatives in the United States and abroad.

Maik Jornitz, Chief Operating Officer of G-Con Manufacturing, has been named as the company’s President charged with leading the pioneering company through its next phase of market growth.

“As we enter this stage of development and look forward to providing our next generation of products, having an experienced and forward thinking leader, like Maik, in this position is invaluable to our organization," said David Shanahan, Chief Executive Officer and Chairman of G-Con’s Board of Directors.

Jornitz joined G-CON in September 2012 as Vice President of Business Development. He was promoted to Chief Operating Officer in March 2013. Before joining G-CON, Jornitz was a Senior Vice President at Sartorius Stedim where he managed their global bioprocess product management and marketing. His career at Sartorius spanned 25 years.

Jornitz received a Masters of Engineering in Bioengineering at the University of Applied Sciences in Hamburg, Germany and successfully completed the PED program at IMD Business School in Lausanne, Switzerland.

In making the announcement, Shanahan further stated, “Since Maik joined G-CON Manufacturing, he has advanced our business into multiple target markets and broadened both the reach and quality of our products. His knowledge and experience within the biopharmaceutical industry has been invaluable. He is a proven leader with an exceptional track record and we are thrilled to have him in this position.”

About G-Con Manufacturing

G-CON was founded to address the fact that existing systems and methodologies for constructing biomanufacturing and personalized medicine suites were neither affordable nor flexible enough to meet the rapidly changing market's needs. G-CON's founders have significant experience in designing, building, operating, and maintaining a variety of traditional biomanufacturing facilities. They are familiar with the excessive cost to build, lack of flexibility, and high expense to maintain these traditional facilities and have leveraged this experience to create the G-CON POD™ solution. Moreover, the G-CON team understands that future facility designs must be multipurpose and repurposable, instead of fixed and specialized with ineffective capacity utilization.

For more information about G-Con, please visit the Company's website at http://www.gconbio.com.

Read the full story at http://www.prweb.com/releases/2014/07/prweb12051552.htm.


'/>"/>
Source: PRWeb
Copyright©2014 Vocus, Inc.
All rights reserved

Related biology technology :

1. GEA Process Engineering and G-CON Manufacturing Announce PCMM Collaboration with Pfizer
2. New 2 Hour Educational Learning Labs at MD&M West Will Feature Baxter Bioscience, BMW, Dell, GE Healthcare, Mattel, Northrup Grumman, Starbucks and Other Leading Groups in Design, Manufacturing, Engineering and Automation
3. Bright Future Ahead for Biopharmaceutical Contract Manufacturing, Says Frost & Sullivan
4. Pharma Contract Manufacturing, Research & Packaging Market a New Report Available at ReportsnReports.com
5. PI Ofers 6-Axis Nanopositioning Stage for Nano-Manufacturing, Microscopy, Nanomanipulation
6. Maine Manufacturing, LLC Announces Global Distribution of FAST® Protein Array Products
7. International Pipette Distributor, Pipette.com Announces the Addition of the Eppendorf Centrifuge 5427 R to Their Product Portfolio
8. Sapphire Energy Announces New CEO James Levine
9. WEDI’s HPID Workgroup Announces Release of Issue Brief: “What is the Difference Between a Health Plan and Payer?”
10. JOLT Announces the Next 6 Startups to Join its Summer 2014 Cohort
11. Texas Biocorridor Announces the Atlas Hotel, Centerpiece of Mixed Use Community for Biotech Industry
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/5/2016)... HILL, N.C. , Feb. 5, 2016  In ... key role for a host of launch activities including ... importance of this launch activity is especially high in ... specialists. Best Practices and the Role of ... will help companies focused on oncology therapies find better ...
(Date:2/4/2016)... Massachusetts , February 4, 2016 - New FDA ... - New FDA action date of July 22, ... of July 22, 2016   - ... U.S. in the past decade indicated for the treatment of signs and symptoms ... Lifitegrast has the potential to be the only product approved in the U.S. ...
(Date:2/4/2016)... Feb. 4, 2016  CytoSorbents Corporation (NASDAQ: ... its flagship CytoSorb® blood filter to treat deadly ... the world, announced that CEO Dr. Phillip ... Source Capital Group,s 2016 Disruptive Growth & Healthcare ... company.  Conference Presentation Details: ...
(Date:2/4/2016)... -- Sinovac Biotech Ltd. ("Sinovac" or the "Company") (NASDAQ: ... in China , today announced that ... on February 4, 2016 a preliminary non-binding proposal letter, ... PKU V-Ming ( Shanghai ) Investment Holdings ... ( Shenzhen ) Fund Management Co., Ltd., ...
Breaking Biology Technology:
(Date:1/20/2016)... Jan. 20, 2016  Synaptics Incorporated (NASDAQ: ... solutions, today announced sampling of S1423, its newest ... and small screen applications including smartwatches, fitness trackers, ... round and rectangular shapes, as well as thick ... with moisture on screen, while wearing gloves, and ...
(Date:1/11/2016)... SAN JOSE, Calif. , Jan. 11, 2016 /PRNewswire/ ... developer of human interface solutions, today announced that its ... display driver integration (TDDI) products won two separate categories ... including Best Mobile Innovator and Best Technology Breakthrough. The ... overall system cost, a simplified supply chain, thinner devices, ...
(Date:1/7/2016)... Various factors have contributed to the ... biologics and biosimilars. Some of these factors include ... demand for cost-effective alternatives, growing burden of chronic ... versions of their corresponding patented biologic drugs, and ... and efficacy. The global biosimilars market is estimated ...
Breaking Biology News(10 mins):